We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

41 hedge funds and large institutions have $5.63M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.03%0.02% (-0.01%)

16% less funds holding

Funds holding: 4941 (-8)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

55% less capital invested

Capital invested by funds: $12.5M → $5.63M (-$6.89M)

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
41
Holders Change
-8
Holders Change %
-16.33%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
8
Increased
4
Reduced
11
Closed
16
Calls
$88K
Puts
Net Calls
+$88K
Net Calls Change
+$19K

YARW Hedge Fund Activity: Q1 2022 in Review

41 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q1 2022, worth a combined $5.63M — down 55% from $12.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of YARW and 8 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 4 added.

The largest buyer was Bailard, opening a new position worth an estimated $92.1K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.22M sold.

  • 41 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q1 2022, down from 49 in Q4 2021.
  • Funds reported $5.63M of Yarrow Bioscience, Inc. Common Stock stock for Q1 2022, down 55% quarter-over-quarter.
  • 8 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q1 2022 and 16 closed out, a net change of -8 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q1 2022 was Bailard, an estimated $92.1K added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q1 2022 was Perceptive Advisors, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2022.